Correction to: Mol Neurobiol
The authors found a terrible mistake in the manuscript. The legends from the Figs. 5 and 6 are interchanged.
The Fig. 5 should be appeared with the legend from the Fig.6 and Fig. 6 should be appeared with the legend from the Fig. 5.
In addition, the authors also found in the Fig. 6 a mistake in the text referring to the order for (a,b,c,d). Please, find below the correct legend for every figure.
Fig. 5 Vandetanib administration induced activation of caspase-3. The vandetanib group showed significantly increased expression of caspase-3 relative to the control group in the striatum (a, c) and in the substantia nigra (b, d) (*P ≤ 0.05)
Fig. 6 Molecular changes in survival pathways after vandetanib administration. No differences were found in the activation of Akt (a, b) or ERK1/2 (c, d) in the vandetanib group relative to the control group
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at https://doi.org/10.1007/s12035-017-0733-x
Rights and permissions
About this article
Cite this article
Requejo, C., Ruiz-Ortega, J.A., Bengoetxea, H. et al. Correction to: Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson’s Disease. Mol Neurobiol 55, 4511 (2018). https://doi.org/10.1007/s12035-018-0979-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-018-0979-y